API market seen topping $339B by 2030 as Lonza leads

The active pharmaceutical ingredients market is projected to exceed $339 billion by 2030, driven by rising demand for innovative and generic drugs, chronic disease treatment and supply-chain localization. Lonza Group AG led API sales in 2025, while North America and the U.S. are expected to remain the largest regional and national markets.

Why it matters: - The API market sits at the center of drug manufacturing, so its growth affects access to medicines, pricing, and supply-chain resilience. - The market’s shift toward high-potency APIs, biologics and complex molecules signals where pharma investment is flowing. - The sector’s fragmentation creates room for more outsourcing, partnerships and capacity expansion.

What happened: - The Business Research Company projected the active pharmaceutical ingredients market will exceed $339 billion by 2030. - The report puts the broader pharmaceuticals market at $2,496 billion by 2030, with APIs accounting for nearly 14% of that value. - The API market is forecast to grow at a 7% compound annual growth rate through 2030. - Lonza Group AG led global API sales in 2025 with a 3% share. - The report lists the top 10 API companies as holding only 14% of total revenue in 2025. - The report includes the full market report and a free sample request.

The details: - Innovative APIs are projected to dominate by 2030 with about 67% of the market, or $226 billion. - Generic APIs remain a major segment, supported by patent expirations and demand for lower-cost medicines. - North America is forecast to lead the market at $132 billion by 2030, up from $101 billion in 2025, a 5% CAGR. - The United States is expected to be the largest single-country market in 2030 at $121 billion, up from $93 billion in 2025. - The U.S. market is expected to grow at a 5% CAGR. - The report says domestic production of specialty and high-potency pharmaceuticals, manufacturing investments and regional sourcing are supporting North American growth. - The U.S. outlook is supported by a pipeline of new drug candidates, outsourcing to CDMOs, quality requirements and continuous manufacturing investment. - Lonza’s biologics and small molecules division supplies APIs, high-potency APIs, biologics manufacturing and contract development and manufacturing services. - The company list also includes Teva Pharmaceutical Industries, Sun Pharmaceutical, Pfizer, Novartis, BASF, Cipla, Aurobindo Pharma, Lupin and Dr. Reddy’s Laboratories. - The supply chain includes raw material providers such as BASF, Evonik, Merck KGaA, Thermo Fisher Scientific and Lonza, with distribution handled by McKesson, Cencora, Cardinal Health and Zuellig Pharma. - End users include Pfizer, Novartis, Roche, Sanofi, AstraZeneca, GSK, Johnson & Johnson and AbbVie.

Between the lines: - The market data suggests scale alone is no longer enough; manufacturers are competing on regulatory compliance, complex chemistry and supply reliability. - The 3% share for the market leader underscores how dispersed the sector remains, which can favor specialized CDMOs and niche API producers. - Growth tied to chronic disease, healthcare access and generic expansion points to demand that is broad-based rather than dependent on one therapy area. - The report highlights September 2024 as a product-development milestone for Lonza, when the company introduced the Innovaform Accelerator at its Colmar, France site to improve API stability, bioavailability and development timelines.

What's next: - The report expects more strategic collaborations, capacity expansions and technology upgrades as demand rises for complex molecules and cost-efficient production. - Companies are likely to keep investing in advanced synthesis methods, AI-enabled manufacturing and greener production techniques. - Innovative APIs and generics are projected to add more than $95 billion in combined market value by 2030, with innovative APIs contributing $64 billion and generics $31 billion. - Chronic disease treatment, healthcare expansion and generic drug uptake are forecast to be the main demand drivers through 2030.

The bottom line: - API manufacturing is entering a growth phase shaped by innovation, outsourcing and regional supply-chain security, with Lonza currently in the lead and the market still highly fragmented.